Related Experiment Video
Updated: Dec 16, 2025
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer
Jennifer Gill1, Jeremy Paul Cetnar1, Vinay Prasad2
1Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.
Abstract:
In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this setting and further research on overall survival benefit is needed to prove drug efficacy.
Insights
Regulatory reviews of immune checkpoint inhibitors for small cell lung cancer reveal delays despite accelerated approvals. Further research is needed to confirm overall survival benefits and drug efficacy.
Area of Science:
- Oncology
- Immunology
- Clinical Trials
Background:
- Small cell lung cancer (SCLC) treatment has limited options.
- Immune checkpoint inhibitors (ICIs) represent a promising therapeutic avenue.
- Regulatory pathways for novel cancer drugs are complex.
Purpose of the Study:
- To review the clinical trial and regulatory approval timeline for ICIs in SCLC.
- To discuss challenges encountered by regulatory agencies during drug approval.
- To highlight paradoxical outcomes of accelerated approval processes.
Main Methods:
- Retrospective review of clinical trial data for approved ICIs in SCLC.
- Analysis of regulatory agency documents and actions.
- Literature synthesis on ICI efficacy and challenges in SCLC.
Main Results:
- Accelerated approval processes did not consistently expedite drug availability in SCLC.
- Significant challenges exist for regulatory agencies in evaluating novel immunotherapies.
- Paradoxical findings suggest a disconnect between initial approval and demonstrated clinical benefit.
Conclusions:
- The current accelerated approval paradigm may not be optimal for SCLC.
- Robust evidence for overall survival benefit is crucial for validating ICI efficacy.
- Further investigation into regulatory strategies and long-term outcomes is warranted.
